| Document Type
|
:
|
BL
|
| Record Number
|
:
|
624635
|
| Doc. No
|
:
|
dltt
|
| Title & Author
|
:
|
Tumor immunology and immunotherapy /\ edited by Robert C. Rees
|
| Edition Statement
|
:
|
First edition
|
| Page. NO
|
:
|
xxvi, 442 pages :: illustrations ;; 26 cm
|
| ISBN
|
:
|
9780199676866 (hbk) :
|
|
|
:
|
: 0199676860 (hbk)
|
| Bibliographies/Indexes
|
:
|
Includes bibliographical references and index
|
| Contents
|
:
|
Machine generated contents note: 1.Adaptive T-cell immunity and tumor antigen recognition / Pierre G Coulie -- 2.Impact of ageing and body mass on cancer immunotherapy outcomes / William J Murphy -- 3.The potential of natural killer cells in cancer immunotherapy / Francesco Colucci -- 4.The tumor microenvironment: The role of tumor-associated macrophages in cancer progression and responses to therapy / Munitta Muthana -- 5.̀Hard' and sòft' loss of MHC class I expression in cancer cells / Federico Garrido -- 6.Modulation of the adaptive immune system through chronic inflammation and T-regulatory responses / Angus G Dalgleish -- 7.Myeloid-derived suppressor cells: Immune-suppressive cells that facilitate tumor progression and promote and deter cancer-associated inflammation / Suzanne Ostrand-Rosenberg -- 8.Triggering death receptors to promote cancer cell death / Neil A Cross -- 9.Identification of tumor antigens for clinical evaluation / Stephanie EB McArdle --
|
|
|
:
|
Contents note continued: 10.Viral antigens as targets for prophylactic and therapeutic intervention in cancer / Kenneth Oguejiofor -- 11.HER2/neu as a target for vaccine and antibody-directed therapies / Sonia A Perez -- 12.Pre-clinical evaluation of immunotherapy: The case for prostate cancer and the TRAMP model / Elena Jachetti -- 13.Tumor-associated antigens characterized in a conceptual framework of biology, microenvironment, and therapy / Mads Hald Andersen -- 14.Predictive biomarkers to better select patients for cancer immunotherapy / Eric Tartour -- 15.Viral platforms for expression of tumor antigens in cancer immunotherapy / Richard Vile -- 16.Translating research into clinical practice: lessons from the immunology and immunotherapy of haemopoietic malignancies / Paul Moss -- 17.DNA vaccines / Victoria A Brentville --
|
|
|
:
|
Contents note continued: 18.Programming the immune system through childhood infections: MUC1 tumor-associated antigen (TAA) as a disease-associated antigen (DAA) / Olivera J Finn -- 19.Vaccination against myeloid leukaemias using newly defined antigens / Barbara-ann Guinn -- 20.Immune-checkpoint blockade in cancer immunotherapy / F Stephen Hodi -- 21.Multi-peptide cancer vaccines for clinical application / Steffen Walter -- 22.Adoptive T-cell therapy using TILs for the treatment of metastatic melanoma / Inge Marie Svane -- 23.Chimeric antigen receptor gene therapy in cancer / David E Gilham -- 24.The vaccinal effect of monoclonal antibodies in cancer therapy / Jean-Luc Teillaud -- 25.Antibody therapies: defining appropriate cell surface epitopes for targeting tumors / Michael Stanglmaier -- 26.Adoptive lymphocyte (stem cell) therapy in cancer / Aurore Saudemont --
|
|
|
:
|
Contents note continued: 27.Cancer stem cells (CSCs) and epithelial-to-mesenchymal transition (EMT): Tumor cell plasticity challenges immunotherapy / Morgan G Mathieu -- 28.Immune escape and ageing of the immune system compromises the immune response to tumor antigens / Graham Pawelec
|
| Abstract
|
:
|
Patients are beginning to benefit from antibody based, cellular and vaccine approaches that are effective against genetically diverse and therapy-resistance cancers. BCG immunotherapy is now being used as a first line treatment for human bladder cancer and the introduction of prophylactic vaccination against Hepatitis B and HPV cancers is starting to show positive results. Following recent FDA approval for a vaccination against prostate cancer, and optimistic results in clinical trials for a vaccine targeting cancer antigens in lung cancer, cancer immunotherapy is now significantly impacting patient clinical management. This text provides an up-to-date and comprehensive account of cancer immunity and immunotherapy. It discusses our adaptive and innate immunity to cancer, the mechanisms underpinning our immune response, current approaches to cancer immunotherapy, and how tumour and host responses can circumvent effective anti-cancer immunity. The book examines recent results, publications and current areas of interest including immune editing and the specific issues that are affecting the research and development of vaccines, providing insight into how these problems may be overcome, as viewed by world leaders in the field. This book will appeal to clinicians working in oncology and cancer immunotherapy, and research scientists including PhD and masters students, post-doctoral researchers and senior investigators
|
| Subject
|
:
|
Cancer-- Immunological aspects
|
| Subject
|
:
|
Cancer-- Immunotherapy
|
| Subject
|
:
|
Neoplasms-- immunology
|
| Dewey Classification
|
:
|
616.994079
|
| LC Classification
|
:
|
QR188.6.T86 2014
|
| Added Entry
|
:
|
Rees, Robert C.
|